Multiple myeloma
| Autor: | Isador Lieberman, Mohamad A. Hussein, Jaya V. Juturi |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Cultural Studies
Cancer Research Stromal cell medicine.medical_treatment Pamidronate Angiogenesis Inhibitors Antineoplastic Agents Zoledronic Acid Arsenicals Education Arsenic Trioxide immune system diseases hemic and lymphatic diseases medicine Humans Dexamethasone Multiple myeloma Bone Marrow Transplantation Diphosphonates Myeloma cell business.industry Imidazoles Oxides medicine.disease Thalidomide Lymphoma Cytokine medicine.anatomical_structure Oncology Apoptosis Immunology Cancer research Bone marrow Multiple Myeloma business medicine.drug |
| Zdroj: | Current Opinion in Internal Medicine. 1:133-137 |
| ISSN: | 1535-5942 |
| DOI: | 10.1097/00132980-200201020-00005 |
| Popis: | Multiple myeloma is a clonal B-cell tumor of slowly proliferating plasma cells within the bone marrow. Among hematologic malignancies, it constitutes 10% of the cancers and ranks as the second most frequently occurring hematologic cancer in the United States, after non-Hodgkin lymphoma. Interleukin-6 is an important cytokine in myeloma cell growth and proliferation. Close cell-to-cell contact between myeloma cells and the bone marrow stromal cells triggers a large amount of interleukin-6 production, which supports the growth of these cells, as well as protecting them from apoptosis induced by dexamethasone and other chemotherapeutic agents. Therapies modulating the tumor and its microenvironment are being actively pursued with the goal of converting multiple myeloma to a chronic disease with the patients maintaining a normal lifestyle. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|